Beta Drugs Q1-FY27 Investor Presentation: Revenue up 25%, PAT rises 41%
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Beta Drugs filed its July 2026 investor presentation. Q1-FY27 consolidated revenue grew 25.2% YoY to INR 1,255 Mn, EBITDA jumped 39.1% to INR 274 Mn with margins expanding 217 bps to 21.83%, and PAT rose 41% to INR 165 Mn. Branded oncology grew 47% YoY and CMO grew 41%. Management guides 20-25% revenue growth for FY27. Vision 2030 targets 51% revenue from domestic branded formulations and 30% from exports by FY30. Recently acquired 66.09% in Nivian Lifesciences (IVF segment). Promoters hold 59.10%.
Strong Q1 beat with margin expansion, clear Vision 2030 targets, and diversification into IVF signal positive long-term growth outlook.